ASS234, as a new Multi-Target Directed propargylamine for Alzheimer’s disease therapy

José Marco-Contelles, Mercedes Unzeta, Gerard Esteban, Rona Ramsay, Alejandro Romero, Ricardo Martínez-Murillo, Maria C. Carreiras, Lhassane Ismaili, Irene Bolea

Research output: Contribution to journalReview articlepeer-review

58 Citations (Scopus)


The complex nature of Alzheimer’s disease (AD) has prompted the design of Multi-Target-Directed Ligands (MTDL) able to bind to diverse biochemical targets involved in the progress and development of the disease. In this context, we have designed a number of MTD propargylamines showing antioxidant, anti-betaamyloid, anti-inflammatory, as well as cholinesterase and monoamine oxidase inhibition capacities. Here, we describe these properties in the MTDL ASS234, our lead-compound ready to enter in pre-clinical studies for AD, as a new multipotent, permeable cholinesterase/monoamine oxidase inhibitor, able to inhibit Aβ- aggregation, possessing antioxidant and neuroprotective properties.
Original languageEnglish
Article number294
Number of pages7
JournalFrontiers in Neuroscience
Publication statusPublished - 28 Jun 2016


  • Multi-target directed ligands,
  • Alzheimer’s disease
  • Monomaine oxidases
  • Cholinesterases
  • Drugs


Dive into the research topics of 'ASS234, as a new Multi-Target Directed propargylamine for Alzheimer’s disease therapy'. Together they form a unique fingerprint.

Cite this